BMRN
Biomarin Pharmaceutical Inc
55.20$
-1.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.3% | 4.3% | 7.2% | 16.7% | 29.7% | 24.8% | 23.4% | 22.4% | 47.5% | 11.4% | 28.8% | 17.0% | 25.2% | |
| 4.4% | 4.2% | 4.2% | 3.7% | 2.5% | 3.2% | 3.0% | 2.2% | 2.4% | 2.3% | 2.1% | 9.9% | 4.5% | |
| 8.3% | 8.5% | 9.0% | 6.7% | 5.8% | 6.9% | 5.1% | 5.8% | 6.3% | 5.4% | 5.7% | 7.6% | 6.3% | |
| 5.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 6.9% | -15.0% | -16.2% | -9.4% | 5.2% | -11.1% | -12.1% | -19.2% | 15.3% | 2.4% | 5.1% | -5.5% | 3.7% | |
| 4.0% | 5.7% | 5.3% | 3.1% | 2.8% | 2.7% | 2.3% | 2.1% | 4.3% | 4.7% | 2.7% | 2.9% | 3.6% | |
| -7.9% | -10.1% | -2.2% | 12.7% | -2.2% | 10.2% | -3.8% | -1.5% | -42.6% | -4.9% | 94.7% | -515.5% | -139.4% | |
| 0.8% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.8% | -0.6% | -7.7% | -2.4% | -0.8% | -0.7% | -5.2% | – | -5.0% | -4.4% | -3.7% | 2.8% | -2.3% | |
| -0.1% | – | – | – | -66.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 110.9% | 282.9% | 107.1% | |
| -0.1% | 1.7% | -6.6% | 1.8% | -66.9% | 0.4% | -5.2% | -0.6% | -0.3% | 0.4% | 106.1% | 276.7% | 104.3% | |
| 15.7% | -4.7% | -1.3% | 31.6% | -39.8% | 35.8% | 14.2% | 20.0% | 4.7% | 7.0% | 229.8% | -222.1% | -10.0% | |
| 19.3% | -1.4% | 2.0% | 13.6% | 26.9% | 22.1% | 21.2% | 20.4% | 43.2% | 6.7% | 26.1% | 14.1% | 21.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.